BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ojeda-uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, Ternant D, Ardizzone M. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 2013;32:695-700. [DOI: 10.1007/s10067-012-2156-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 9.1] [Reference Citation Analysis]
2 Raffray L, Guillevin L. Rituximab treatment of ANCA-associated vasculitis. Expert Opin Biol Ther 2020;20:899-910. [PMID: 32293192 DOI: 10.1080/14712598.2020.1748597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Martínez López JA, García Vivar ML, Cáliz R, Freire M, Galindo M, Hernández MV, López Longo FJ, Martínez Taboada V, Pego Reigosa JM, Rubio E, Trujillo E, Vela-Casasempere P. Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding. Reumatol Clin 2017;13:264-81. [PMID: 27321859 DOI: 10.1016/j.reuma.2016.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
4 Longhitano E, Zirino F, Calabrese V, Giuffrida A, Gembillo G, Cernaro V, Masturzo B, Attini R, Torreggiani M, Piccoli GB, Santoro D. Commonly used immunosuppressive drugs for kidney diseases and pregnancy: focus on open questions. Expert Rev Clin Pharmacol 2021;:1-3. [PMID: 34402354 DOI: 10.1080/17512433.2021.1968831] [Reference Citation Analysis]
5 Moroni G, Ponticelli C. Pregnancy in women with systemic lupus erythematosus (SLE). European Journal of Internal Medicine 2016;32:7-12. [DOI: 10.1016/j.ejim.2016.04.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 6.2] [Reference Citation Analysis]
6 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
7 Ponticelli C, Moroni G. Immunosuppression in pregnant women with systemic lupus erythematosus. Expert Rev Clin Immunol 2015;11:549-52. [PMID: 25842985 DOI: 10.1586/1744666X.2015.1033404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
8 Vicente Rabaneda EF, Herrero-Beaumont G, Castañeda S. Update on the use of abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2013;9:599-621. [PMID: 23899231 DOI: 10.1586/1744666X.2013.811192] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Sarno MA, Mancari R, Azim HA, Colombo N, Peccatori FA. Are monoclonal antibodies a safe treatment for cancer during pregnancy? Immunotherapy 2013;5:733-41. [DOI: 10.2217/imt.13.64] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
10 Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol 2018;11:987-98. [PMID: 30227748 DOI: 10.1080/17512433.2018.1525293] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
11 Kumar M, Ray L, Vemuri S, Simon TA. Pregnancy outcomes following exposure to abatacept during pregnancy. Seminars in Arthritis and Rheumatism 2015;45:351-6. [DOI: 10.1016/j.semarthrit.2015.06.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
12 Mittel RJ, Tobin MC, Kulik J. Neonatal B-cell suppression after in utero exposure to R-CHOP. Ann Allergy Asthma Immunol 2013;111:221-2. [PMID: 23987200 DOI: 10.1016/j.anai.2013.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS, Le Guillou AC, Yakoub-Agha I, Dharancy S, Noel C, Vantyghem MC. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 2015;10:136. [PMID: 26490561 DOI: 10.1186/s13023-015-0332-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
14 Balbi GGM, Domingues V, Balbi GGM, De Jesús GR, Levy RA. Use of synthetic and biologic DMARDs during pregnancy. Expert Rev Clin Immunol 2019;15:27-39. [PMID: 30365902 DOI: 10.1080/1744666X.2019.1541739] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Puchner A, Gröchenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, Högenauer C, Koch R, Hermann J, Studnicka-Benke A, Weger W, Puchner R, Dejaco C. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.Wien Klin Wochenschr. 2019;131:29-44. [PMID: 30643992 DOI: 10.1007/s00508-019-1448-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
16 Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm 2018;5:e453. [PMID: 29564373 DOI: 10.1212/NXI.0000000000000453] [Cited by in Crossref: 88] [Cited by in F6Publishing: 32] [Article Influence: 29.3] [Reference Citation Analysis]
17 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 4.4] [Reference Citation Analysis]
18 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi-Monadi S, Akhlaghdoust M, Elikaei Behjati S, Jafarieh A. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol 2019;38:2977-94. [PMID: 31367943 DOI: 10.1007/s10067-019-04699-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
20 Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 2016;19:834-43. [PMID: 27125255 DOI: 10.1111/1756-185X.12860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opinion on Drug Safety 2014;13:1591-9. [DOI: 10.1517/14740338.2014.951326] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
22 Bowman CJ, Breslin WJ, Connor AV, Martin PL, Moffat GJ, Sivaraman L, Tornesi MB, Chivers S. Placental Transfer of Fc-Containing Biopharmaceuticals across Species, an Industry Survey Analysis: PLACENTAL TRANSFER OF Fc BIOPHARMACEUTICALS. Birth Defects Res B 2013;98:459-85. [DOI: 10.1002/bdrb.21089] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
23 Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Review of Vaccines 2016;15:239-56. [DOI: 10.1586/14760584.2016.1115351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
24 Colla L, Diena D, Rossetti M, Manzione AM, Marozio L, Benedetto C, Biancone L. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. J Nephrol 2018;31:361-83. [DOI: 10.1007/s40620-018-0477-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
25 Amaral LM, Cunningham MW Jr, Cornelius DC, LaMarca B. Preeclampsia: long-term consequences for vascular health. Vasc Health Risk Manag 2015;11:403-15. [PMID: 26203257 DOI: 10.2147/VHRM.S64798] [Cited by in Crossref: 15] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
26 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. WJR 2015;5:50. [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
27 Vasanthamohan L, Choo S, Marshall T, Symons YT, Matsui D, Eastabrook G, Solh Z. Peripartum hyperhemolysis prophylaxis and management in sickle cell disease: A case report and narrative review. Transfusion 2020;60:2448-55. [PMID: 32851670 DOI: 10.1111/trf.16003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Østensen M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol 2017;10:661-9. [PMID: 28326845 DOI: 10.1080/17512433.2017.1305268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
29 Moffat GJ, Retter MW, Kwon G, Loomis M, Hock MB, Hall C, Bussiere J, Lewis EM, Chellman GJ. Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation. Birth Defects Res B Dev Reprod Toxicol 2014;101:178-88. [PMID: 24753333 DOI: 10.1002/bdrb.21105] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
30 Soh MC, Moretto M. The use of biologics for autoimmune rheumatic diseases in fertility and pregnancy. Obstet Med 2020;13:5-13. [PMID: 32284726 DOI: 10.1177/1753495X19841799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Soh MC, Nelson-piercy C. High-risk pregnancy and the rheumatologist. Rheumatology 2015;54:572-87. [DOI: 10.1093/rheumatology/keu394] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 6.9] [Reference Citation Analysis]
32 Tavakolpour S, Mirsafaei HS, Delshad S. Management of pemphigus disease in pregnancy. Am J Reprod Immunol 2017;77:e12601. [DOI: 10.1111/aji.12601] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
33 Dallmann A, Pfister M, van den Anker J, Eissing T. Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models. Clin Pharmacol Ther 2018;104:1110-24. [PMID: 29633257 DOI: 10.1002/cpt.1084] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
34 Gualtierotti R, Ingegnoli F, Meroni PL. Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al. Clin Rheumatol 2013;32:727-8. [PMID: 23636791 DOI: 10.1007/s10067-013-2241-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]